Glenmark Pharmaceuticals reported strong Q3 FY26 results with consolidated revenue rising 15.1% year-on-year to Rs 39.01 billion and net profit increasing 15.9% to Rs 4.03 billion. Growth was driven by robust performance in India and North America, margin expansion, and improved product mix across geographies.
Show moreStay Ahead – Explore Now! IndiGo Cancels Flights To Central Asia Until February 28
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
